Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review

Helicobacter pylori is a spiral-shaped gram-negative bacteria associated with peptic ulcer, gastritis and gastric cancer. H.pylori-pooled overall prev...

Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer

Tegoprazan is a novel potassium-competitive acid blocker for the treatment of acid-related disorders. In a phase 3, double-blind, active control, mult...

Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials

Study looked for randomized controlled trials that examined the efficacy and safety of gastrointestinal bleeding prophylaxis with PPIs, H2RAs, or sucr...

Laryngopharyngeal reflux, gastroesophageal reflux and dental disorders: A systematic review

Study results supported a higher prevalence of dental erosion and caries in reflux patients compared with healthy individuals. The involvement of refl...

Statins and risk of peptic ulcer disease: A systematic review and meta-analysis

Peptic ulcer disease (PUD) is one of the most common gastrointestinal disorders worldwide. Studies have suggested the protective effect of statins aga...

Is there an association between peptic ulcer disease and osteoporosis: a systematic review and cumulative analysis

Peptic ulcer disease (PUD) sufferers are at a high risk of developing osteoporosis, but the evidence has not been previously synthesized. This is the...

The role of endoscopic doppler probe in the management of bleeding peptic ulcers: a systematic review and meta-analysis

The endoscopic doppler probe (DOP-US) identifies arterial blood flow at the base to direct therapy. We performed a systematic review and meta-analysis...

Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial

Lansoprazole was either given twice daily for 16 weeks or matched to placebo. Primary outcome was symptomatic response at 16 weeks measured using the...